Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma
Sponsor study identifier
Secondary identifiers
interventional
25
1 country
1
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
June 28, 2005
Actual (reported)June 29, 2005
Actual (reported)December 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
anti-tumor effects and systemic immune activation at 28 days
tumor response
toxicity and safety
the induction of antigen-specific T-lymphocytes after multiple cycles of treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Casciello F, Kelly GM, Ramarao-Milne P, Kamal N, Stewart TA, Mukhopadhyay P, Kazakoff SH, Miranda M, Kim D, Davis FM, Hayward NK, Vertino PM, Waddell N, Gannon F, Lee JS. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis. Cancer Res. 2022 Apr 1;82(7):1208-1221. doi: 10.1158/0008-5472.CAN-21-2218.
Kevin B Kim, MD
UT MD Anderson Cancer Center
First Submitted
June 28, 2005
First Posted
June 29, 2005
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 2006
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 1, 2008
Record last verified: 2008-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: